PCG
REGN icon

Prosperity Consulting Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Prosperity Consulting Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$278K Buy
360
+20
+6% +$15.3K 0.01% 433
2025
Q4 		$262K Buy
+340
New +$231K 0.01% 440
2024
Q4 		– Sell
-222
Closed -$233K – 477
2024
Q3 		$233K Buy
+222
New +$247K 0.02% 418

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Prosperity Consulting Group's REGN Position: Q1 2026 in Review

Prosperity Consulting Group increased its Regeneron Pharmaceuticals (REGN) stake by 5.9% in Q1 2026, buying an estimated $15.3K and bringing the position to 360 shares worth $278K. The position accounts for 0.01% of the portfolio, ranked #433.

Prosperity Consulting Group first reported a position in REGN in Q3 2024 and has held it in 3 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Prosperity Consulting Group held 360 shares of Regeneron Pharmaceuticals worth $278K as of Q1 2026.
  • Prosperity Consulting Group bought 20 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $15.3K.
  • Regeneron Pharmaceuticals made up 0.01% of Prosperity Consulting Group's portfolio in Q1 2026, its #433 holding.
  • Prosperity Consulting Group first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Prosperity Consulting Group's 13F filing for Q1 2026, filed 5 May 2026.